Register for our free email digests:
Latest From Serum Institute of India Ltd.
India’s Hilleman Laboratories, in partnership with a government agency, expects to start human trials this year with a pioneering multivalent vaccine to prevent shigellosis, a highly contagious bacterial diarrheal disease that is a major killer of children in low-income countries but has proven a difficult vaccine target.
India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.
Despite many restrictions, the nation is a potential market for imported drugs.
Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Laboratory Testing Services
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Psychemedics Corp.
- Senior Management
Raymond C Kubacki, Chmn., Pres. & CEO
Neil Lerner, VP, Fin.
Jim Dyke, Corp. VP, Sales & Mktg.
- Contact Info
Phone: (978) 206-8220
125 Nagog Pk.
Acton, MA 01720
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.